Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia

NCT02277847 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Idarubicin(8mg/m2) and cytosine arabinoside
DRUG: Idarubicin(10mg/m2), cytosine arabinoside

Sponsor

Guangdong Provincial People's Hospital